Sign In
Buy WST
$358.48
-3.89 (-1.07%)
At Close: Jul 17, 2026
West Pharmaceutical (WST) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Wednesday, 29'th Apr 2026
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for April 29th
11:15am, Wednesday, 29'th Apr 2026
FIX, DVN and WST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 29th, 2026.
From Slide to Surge: How West Pharmaceutical Services Reclaimed Its Mojo in 2026
08:15am, Tuesday, 28'th Apr 2026
West Pharmaceutical Services (NYSE: WST | WST Price Prediction) has ripped 24.2% in the past month and 8.7% in the past week, and the move has the fingerprints of a sustained re-rating.
West to Participate in Upcoming Investor Conferences
06:00am, Tuesday, 28'th Apr 2026
EXTON, Pa., April 28, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will pre
Here's Why West Pharmaceutical Services (WST) is a Strong Growth Stock
10:46am, Monday, 27'th Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
West Pharmaceutical Services, Inc. (NYSE:WST) Given Average Rating of “Moderate Buy” by Brokerages
02:22am, Monday, 27'th Apr 2026
Shares of West Pharmaceutical Services, Inc. (NYSE: WST - Get Free Report) have received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Mark
HB Wealth Management LLC Sells 3,325 Shares of West Pharmaceutical Services, Inc. $WST
04:00am, Sunday, 26'th Apr 2026
HB Wealth Management LLC decreased its position in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 27.3% during the fourth quarter, according to its most recent Form 13F filing with the Se
West Pharmaceutical: A High-Quality Beat-And-Raise With More Upside Ahead
08:19am, Friday, 24'th Apr 2026
West Pharmaceutical Services delivered a beat-and-raise 1Q26, with adjusted EPS of $2.13 and revenue of $844.9M, both well ahead of expectations. WST's growth is driven by robust demand for High-Value
West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
01:42pm, Thursday, 23'rd Apr 2026
West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the company's first-quarter 2026 earnings surpassed analyst estimates.
WST Stock Jumps on Q1 Earnings & Sales Beat, EPS View Up on HVP Growth
01:36pm, Thursday, 23'rd Apr 2026
West Pharmaceutical posts 46.9% EPS growth and beats estimates as strong segment demand lifts revenues, prompting a higher 2026 outlook and margin expansion.
West Pharmaceutical Services, Inc. (WST) Q1 2026 Earnings Call Transcript
12:01pm, Thursday, 23'rd Apr 2026
West Pharmaceutical Services, Inc. (WST) Q1 2026 Earnings Call Transcript
Compared to Estimates, West Pharmaceutical (WST) Q1 Earnings: A Look at Key Metrics
10:31am, Thursday, 23'rd Apr 2026
The headline numbers for West Pharmaceutical (WST) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Stre
West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates
08:15am, Thursday, 23'rd Apr 2026
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.45 per share a year ago
On April 23, 2026, West Pharmaceutical Services Inc (WST) released its 8-K filing reporting first-quarter 2026 results. The company posted net sales of $844.9 m
West Pharma lifts 2026 profit forecast on strong demand for medical equipment
07:03am, Thursday, 23'rd Apr 2026
West Pharmaceutical on Thursday raised its annual profit and revenue forecasts after beating estimates for first-quarter results, betting on strong demand for its proprietary products that include
